Dharamsaktu Deepsikha, Bharti Jyotsna Naresh, Elhence Poonam, Rao Meenakshi, Vishnoi Jeewan Ram, Soni Subash Chandra, Rustagi Neeti
Department of Pathology, All India Institute of Medical Science, Jodhpur, Rajasthan India.
Department of Pathology, All India Institute of Medical Sciences, Mangalagiri, Guntur, India.
Indian J Surg Oncol. 2025 Apr;16(2):685-690. doi: 10.1007/s13193-024-02122-6. Epub 2024 Nov 7.
Peroxisome proliferator activator receptor γ (PPAR γ) activation may be responsible for inhibiting the growth of cancer cell lines, and drugs that activate PPAR γ may have therapeutic benefits. Therefore, a mutation in peroxisome proliferator activator receptor γ can produce carcinogenesis. This present study aims to assess the expression of PPAR γ by immunohistochemistry in colorectal carcinoma and its correlation with clinicopathological characteristics. Most of the cases were elderly males, and pelvic pain and bleeding were the predominant symptoms. Colon carcinoma was more common than rectal carcinoma. The adenocarcinoma NOS and mucinous carcinoma were the common histological types, and 40% cases showed lymph node metastasis. The PPAR γ expression was present in 61.8% of the patients, and it showed a significant correlation with lymph node metastasis and tumor location ( = 0.05 and = 0.04). The overall survival was slightly higher but non-significant in patients with positive PPAR γ expression than negative ones ( = 0.7). The multivariate analysis revealed that nodal metastasis, lymphovascular invasion, and tumor-infiltrating lymphocytes were the independent prognostic factors for colorectal carcinoma. The PPAR γ expression showed a significant correlation with lymph node metastasis and tumor location. Thus, we hypothesized that the PPAR γ expression might affect the overall survival in colorectal cancer. However, more studies with larger sample size are required to understand the nature of colorectal cancer expressing PPAR γ which might benefit the patient therapeutically in future.
过氧化物酶体增殖物激活受体γ（PPARγ）的激活可能是抑制癌细胞系生长的原因，激活PPARγ的药物可能具有治疗益处。因此，过氧化物酶体增殖物激活受体γ的突变可能会导致致癌作用。本研究旨在通过免疫组织化学评估PPARγ在结直肠癌中的表达及其与临床病理特征的相关性。大多数病例为老年男性，主要症状为盆腔疼痛和出血。结肠癌比直肠癌更常见。腺癌NOS和黏液癌是常见的组织学类型，40%的病例出现淋巴结转移。61.8%的患者存在PPARγ表达，其与淋巴结转移和肿瘤位置显著相关（P = 0.05和P = 0.04）。PPARγ表达阳性的患者总生存率略高于阴性患者，但差异无统计学意义（P = 0.7）。多因素分析显示，淋巴结转移、淋巴管浸润和肿瘤浸润淋巴细胞是结直肠癌的独立预后因素。PPARγ表达与淋巴结转移和肿瘤位置显著相关。因此，我们推测PPARγ表达可能影响结直肠癌的总生存率。然而，需要更多样本量更大的研究来了解表达PPARγ的结直肠癌的本质，这可能在未来对患者治疗有益。
